Quantitative Cross-linking Lens

UV Delivery + Biomechanical Monitoring

CXLens® is applied to the scleral surface of the eye (vaulting over the cornea) following administration of Vitamin B2 (Riboflavin) eye drops. CXLens initiates emission of patterned Ultraviolet (UV) light driving corneal cross-linking (CXL). CXLens UV illumination continues until an on-board sensor and algorithms determine that certain bio-mechanical properties of the corneal stroma have changed to within predetermined limits. From this closed-loop dosing paradigm, control of precise permanent corneal shape change (refractive correction) is achieved.

TECLens System

Comfortable, Precise, Stable Targeting

The scleral design of CXLens is very comfortable for the patient and stable on the eye. Patients can be treated with eyes opened or closed sitting upright in a chair. The contact lens form factor is familiar to contact lens wearers, eliminating the fear associated with laser correction procedures.

qCXL(TM) for Accurate Refractions

CXLens is unique in the corneal cross-linking field enabling Quantitative Cross-linking (qCXL). Sitting directly on the eye, it’s built-in Ultrasound transducer provides real-time elastography feedback during cross-linking enabling precise closed-loop dosing (selective stiffening of the corneal surface) required for accurate refractive outcomes.

CXLens cross-section

US Transduer

CXLens Ultrasound Transducer

Ultrasound is transmitted through the UV beam (not possible with stand-off off-eye systems) to measure real-time qCXL parameters including:

TECLens / SERVImed Proprietary Trans-Epithelial Riboflavin

Accelerated Cross-linking

CXLens provides a Comfortable High Oxygen Environment for Accelerated Cross-linking with our proprietary cross-linking fluid. Oxygen is an important factor in CXL. Supplemental Oxygen speeds up the reaction. Our proprietary cross-linking fluid:

Simplicity and Scale

TECLens System

TECLens provides the most technologically advanced cross-linking platform without sacrificing operational simplicity and affordability.


For Patients

For Physicians

Target Indications

Progressive Keratoconus

Low Myopia



Corneal Ectasia following refractive surgery

Refractive Tune-up after IOL placement

US Patents 9,883,970  | 9,861,526  |  9,907,698 |  10,010,449 | 10,548,772 | 10,548,773 (and corresponding OUS Patents), and several Patents Pending. TECLens® & CXLens® are Registered Trademarks of TECLens, LLC

Quantitative Corneal Cross-linking” , “Quantitative Cross-linking” & “qCXL” ©2020 TECLens, LLC All rights reserved.